Tag: Hatch-Waxman Act

Explore how pharmaceutical companies use authorized generics to maintain revenue and fight competition after patent expiration, including their impact on drug prices.

An ANDA is the FDA pathway that lets generic drug makers prove their products match brand-name drugs in safety and effectiveness - without repeating costly clinical trials. It’s why 90% of prescriptions are filled with generics that cost far less.

After the first generic enters the market, multiple competitors rush in, causing prices to plummet. Learn how authorized generics, PBM contracts, and manufacturing risks shape the chaotic race to sell cheap drugs.

First generics and authorized generics both offer cheaper versions of brand-name drugs, but timing of market entry changes everything. When the brand company launches its own generic at the same time, it splits the market and limits price drops - costing patients and insurers billions.

The FDA's 180-day exclusivity gives the first generic drug maker to challenge a patent a head start in the market. It lowers drug prices-but loopholes let companies delay launches, costing patients billions.